{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:21:50Z","timestamp":1781594510291,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10147-025-02826-x","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T22:38:23Z","timestamp":1751755103000},"page":"1787-1796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing"],"prefix":"10.1007","volume":"30","author":[{"given":"Nobuaki","family":"Mamesaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8188-2505","authenticated-orcid":false,"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,6]]},"reference":[{"key":"2826_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma SV, Bell DW, Settleman J et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169\u2013181. https:\/\/doi.org\/10.1038\/nrc2088","journal-title":"Nat Rev Cancer"},{"key":"2826_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","volume":"142","author":"RP Graham","year":"2018","unstructured":"Graham RP, Treece AL, Lindeman NI et al (2018) Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med 142:163\u2013167. https:\/\/doi.org\/10.5858\/arpa.2016-0579-CP","journal-title":"Arch Pathol Lab Med"},{"key":"2826_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 107:1179\u20131186. https:\/\/doi.org\/10.1111\/cas.12996","journal-title":"Cancer Sci"},{"key":"2826_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107798","volume":"191","author":"M Okahisa","year":"2024","unstructured":"Okahisa M, Udagawa H, Matsumoto S et al (2024) Clinical outcomes in patients with non-small cell lung cancer harboring EGFR exon20 in-frame insertions in the near-loop and far-loop: results from LC-SCRUM-Asia. Lung Cancer 191:107798. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107798","journal-title":"Lung Cancer"},{"key":"2826_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","volume":"16","author":"A Passaro","year":"2021","unstructured":"Passaro A, Mok T, Peters S et al (2021) Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol 16:764\u2013773. https:\/\/doi.org\/10.1016\/j.jtho.2020.12.002","journal-title":"J Thorac Oncol"},{"key":"2826_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12032-017-0985-3","volume":"34","author":"MK Stein","year":"2017","unstructured":"Stein MK, Morris L, Sullivan JL et al (2017) Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing. Med Oncol 34:126. https:\/\/doi.org\/10.1007\/s12032-017-0985-3","journal-title":"Med Oncol"},{"key":"2826_CR7","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1038\/s41467-024-45594-4","volume":"15","author":"TK Hayes","year":"2024","unstructured":"Hayes TK, Aquilanti E, Persky NS et al (2024) Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nat Commun 15:2742. https:\/\/doi.org\/10.1038\/s41467-024-45594-4","journal-title":"Nat Commun"},{"key":"2826_CR8","doi-asserted-by":"publisher","first-page":"e1070","DOI":"10.1634\/theoncologist.2018-0572","volume":"24","author":"S Wen","year":"2019","unstructured":"Wen S, Dai L, Wang L et al (2019) Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer. Oncologist 24:e1070\u2013e1081. https:\/\/doi.org\/10.1634\/theoncologist.2018-0572","journal-title":"Oncologist"},{"key":"2826_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/15384047.2016.1139235","volume":"17","author":"EY Kim","year":"2016","unstructured":"Kim EY, Cho EN, Park HS et al (2016) Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 17:237\u2013245. https:\/\/doi.org\/10.1080\/15384047.2016.1139235","journal-title":"Cancer Biol Ther"},{"key":"2826_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","volume":"8","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Canepa HM, Bailey AS et al (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8:45\u201351. https:\/\/doi.org\/10.1097\/JTO.0b013e3182781e35","journal-title":"J Thorac Oncol"},{"key":"2826_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/curroncol29010024","volume":"29","author":"I Attili","year":"2022","unstructured":"Attili I, Passaro A, Pisapia P et al (2022) Uncommon EGFR compound mutations in non-small cell lung cancer (NSCLC): a systematic review of available evidence. Curr Oncol 29:255\u2013266. https:\/\/doi.org\/10.3390\/curroncol29010024","journal-title":"Curr Oncol"},{"key":"2826_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s10147-013-0602-1","volume":"19","author":"B Keam","year":"2014","unstructured":"Keam B, Kim DW, Park JH et al (2014) Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol 19:594\u2013600. https:\/\/doi.org\/10.1007\/s10147-013-0602-1","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"2826_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","volume":"19","author":"M Borgeaud","year":"2024","unstructured":"Borgeaud M, Parikh K, Banna GL et al (2024) Unveiling the landscape of uncommon EGFR mutations in NSCLC-a systematic review. J Thorac Oncol 19(7):973\u2013983. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.016","journal-title":"J Thorac Oncol"},{"key":"2826_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147908","volume":"25","author":"A Szpechcinski","year":"2024","unstructured":"Szpechcinski A, Moes-Sosnowska J, Skronska P et al (2024) The advantage of targeted next-generation sequencing over qPCR in testing for druggable EGFR variants in non-small-cell lung cancer. Int J Mol Sci 25:7908. https:\/\/doi.org\/10.3390\/ijms25147908","journal-title":"Int J Mol Sci"},{"key":"2826_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","volume":"139","author":"AC Tan","year":"2020","unstructured":"Tan AC, Lai GGY, Tan GS et al (2020) Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer 139:207\u2013215. https:\/\/doi.org\/10.1016\/j.lungcan.2019.11.022","journal-title":"Lung Cancer"},{"key":"2826_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"key":"2826_CR17","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388. https:\/\/doi.org\/10.1056\/NEJMoa0909530","journal-title":"N Engl J Med"},{"key":"2826_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239\u2013246. https:\/\/doi.org\/10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"key":"2826_CR19","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JCH, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327\u20133334. https:\/\/doi.org\/10.1200\/JCO.2012.44.2806","journal-title":"J Clin Oncol"},{"key":"2826_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"2826_CR21","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1097\/JTO.0b013e318227e8c6","volume":"6","author":"T De Pas","year":"2011","unstructured":"De Pas T, Toffalorio F, Manzotti M et al (2011) Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 6:1895\u20131901. https:\/\/doi.org\/10.1097\/JTO.0b013e318227e8c6","journal-title":"J Thorac Oncol"},{"key":"2826_CR22","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","volume":"17","author":"JY Wu","year":"2011","unstructured":"Wu JY, Yu CJ, Chang YC et al (2011) Effectiveness of tyrosine kinase inhibitors on \u2018uncommon\u2019 epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812\u20133821. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3408","journal-title":"Clin Cancer Res"},{"key":"2826_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/annonc\/mdt418","volume":"25","author":"M Beau-Faller","year":"2014","unstructured":"Beau-Faller M, Prim N, Ruppert AM et al (2014) Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 25:126\u2013131. https:\/\/doi.org\/10.1093\/annonc\/mdt418","journal-title":"Ann Oncol"},{"key":"2826_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","volume":"10","author":"CH Chiu","year":"2015","unstructured":"Chiu CH, Yang CT, Shih JY et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I mutations. J Thorac Oncol 10:793\u2013799. https:\/\/doi.org\/10.1097\/JTO.0000000000000504","journal-title":"J Thorac Oncol"},{"key":"2826_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jtho.2015.12.107","volume":"11","author":"B Klughammer","year":"2016","unstructured":"Klughammer B, Brugger W, Cappuzzo F et al (2016) Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations. J Thorac Oncol 11:545\u2013555. https:\/\/doi.org\/10.1016\/j.jtho.2015.12.107","journal-title":"J Thorac Oncol"},{"key":"2826_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2016.01.018","volume":"96","author":"J Xu","year":"2016","unstructured":"Xu J, Jin B, Chu T et al (2016) EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China. Lung Cancer 96:87\u201392. https:\/\/doi.org\/10.1016\/j.lungcan.2016.01.018","journal-title":"Lung Cancer"},{"key":"2826_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","volume":"12","author":"E Castellanos","year":"2017","unstructured":"Castellanos E, Feld E, Horn L (2017) Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer. J Thorac Oncol 12:612\u2013623. https:\/\/doi.org\/10.1016\/j.jtho.2016.12.014","journal-title":"J Thorac Oncol"},{"key":"2826_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2019.06.025","volume":"119","author":"LC Chang","year":"2019","unstructured":"Chang LC, Lim CK, Chang LY et al (2019) Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer 119:77\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2019.06.025","journal-title":"Eur J Cancer"},{"key":"2826_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Sequist LV, Geater SL et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16:830\u2013838. https:\/\/doi.org\/10.1016\/S1470-2045(15)00026-1","journal-title":"Lancet Oncol"},{"key":"2826_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","volume":"10","author":"Y Okuma","year":"2024","unstructured":"Okuma Y, Kubota K, Shimokawa M et al (2024) First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncol 10:43\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5013","journal-title":"JAMA Oncol"},{"key":"2826_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline. version 1.1. Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2826_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310. https:\/\/doi.org\/10.1016\/0197-2456(89)90015-9","journal-title":"Control Clin Trials"},{"key":"2826_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-02007","author":"S Miura","year":"2025","unstructured":"Miura S, Tanaka H, Misumi T et al (2025) Pragmatic randomized study of afatinib versus chemotherapy for patients with non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: ACHILLES\/TORG1834. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco-24-02007","journal-title":"J Clin Oncol"},{"key":"2826_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho JH, Lim SH, An HJ et al (2020) Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 38:488\u2013495. https:\/\/doi.org\/10.1200\/JCO.19.00931","journal-title":"J Clin Oncol"},{"key":"2826_CR35","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","volume":"597","author":"JP Robichaux","year":"2021","unstructured":"Robichaux JP, Le X, Vijayan RSK et al (2021) Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597:732\u2013737. https:\/\/doi.org\/10.1038\/s41586-021-03898-1","journal-title":"Nature"},{"key":"2826_CR36","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2016.05.007","volume":"11","author":"K Leventakos","year":"2016","unstructured":"Leventakos K, Kipp BR, Rumilla KM et al (2016) S768I mutation in EGFR in patients with lung cancer. J Thorac Oncol 11:1798\u20131801. https:\/\/doi.org\/10.1016\/j.jtho.2016.05.007","journal-title":"J Thorac Oncol"},{"key":"2826_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108878","volume":"24","author":"G Pretelli","year":"2023","unstructured":"Pretelli G, Spagnolo CC, Ciappina G et al (2023) Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need. Int J Mol Sci 24:8878. https:\/\/doi.org\/10.3390\/ijms24108878","journal-title":"Int J Mol Sci"},{"key":"2826_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101994","volume":"85","author":"V Gristina","year":"2020","unstructured":"Gristina V, Malapelle U, Galvano A et al (2020) The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat Rev 85:101994. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101994","journal-title":"Cancer Treat Rev"},{"key":"2826_CR39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1158\/1078-0432.CCR-22-3497","volume":"29","author":"MJ Grant","year":"2023","unstructured":"Grant MJ, Aredo JV, Starrett JH et al (2023) Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. Clin Cancer Res 29:2123\u20132130. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3497","journal-title":"Clin Cancer Res"},{"key":"2826_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100791","volume":"13","author":"CW Xu","year":"2020","unstructured":"Xu CW, Lei L, Wang WX et al (2020) Molecular characteristics and clinical outcomes of EGFR exon 19 C-helix deletion in non-small cell lung cancer and response to EGFR TKIs. Transl Oncol 13:100791. https:\/\/doi.org\/10.1016\/j.tranon.2020.100791","journal-title":"Transl Oncol"},{"key":"2826_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan6566","volume":"9","author":"S Kohsaka","year":"2017","unstructured":"Kohsaka S, Nagano M, Ueno T et al (2017) A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med 9:eaan6566. https:\/\/doi.org\/10.1126\/scitranslmed.aan6566","journal-title":"Sci Transl Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02826-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02826-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02826-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:05:24Z","timestamp":1756389924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02826-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,6]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2826"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02826-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,6]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N. Mamesaya received grants and personal fees from Boehringer Ingelheim Co., Ltd., MSD K.K., and Chugai Pharmaceutical Co., LTD., grants from Arrivent Biopharma, and personal fees from Novartis Pharma K.K., Taiho Pharmaceutical., AstraZeneca K.K., Bristol-Myers Squibb Japan, and Ono Pharmaceutical Co., LTD. outside the submitted work. H. Kobayashi received personal fees from Eli Lilly K.K., Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. outside the submitted work. S. Omori received grants and personal fees from Daiichi-Sankyo Co., Ltd. and additional personal fees from Chugai Pharmaceutical Co., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Taiho Pharmaceuticals, Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Amgen K.K. outside the submitted work. R. Ko received grants from Boehringer Ingelheim Co., Ltd. and MSD K.K. and personal fees from Boehringer Ingelheim Co., Ltd., Taiho Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Eli Lilly K.K., Pfizer Inc., and AstraZeneca K.K. outside the submitted work. K. Wakuda received grants and personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K., and Daiichi Sankyo Co., Ltd. and grants from Novartis Pharma K.K., AbbVie, Amgen K.K., Taiho Pharmaceutical; Boehringer Ingelheim, Eli Lilly K.K., Ono Pharmaceutical, Janssen Pharmaceutical K.K., Takeda Pharmaceutical, and Nihon Kayaku outside of the submitted work. A. Ono received personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. outside of the submitted work. T. Naito received grants from Otsuka Pharmaceutical K.K. and personal fees from Ono Pharmaceutical Co., Ltd. and Helsinn Healthcare SA outside the submitted work. H. Kenmotsu received grants and personal fees from AstraZeneca K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and Eli Lilly K.K. and personal fees from Amgen K.K., Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Daiichi-Sankyo Co., Ltd., Loxo Oncology, Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceuticals, Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K. K., and Pfizer Inc. outside the submitted work. H. Murakami received grants and personal fees from AstraZeneca K.K., Takeda Pharmaceutical Co., Ltd., AbbVie, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., and IQvia and personal fees from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Japan, MSD K.K., Pfizer Inc., Novartis Pharma K.K., Eli Lilly Japan K.K., Taiho Pharmaceuticals, Boehringer Ingelheim, Eisai, and Nihon Kayaku outside the submitted work. T. Takahashi received grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., MSD, Pfizer Inc., Boehringer Ingelheim, Merck Biopharma Co., Ltd., Amgen K.K., Roche Diagnostics K.K., and Takeda Pharmaceuticals Co., Ltd. and personal fees from Yakult Honsha Co., Ltd. outside the submitted work. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}